宫颈癌伴肺转移包括寡转移的放射治疗。
Radiation Therapy for Uterine Cervical Cancer With Lung Metastases Including Oligometastases.
机构信息
Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
出版信息
In Vivo. 2019 Sep-Oct;33(5):1677-1684. doi: 10.21873/invivo.11655.
BACKGROUND/AIM: To investigate the role and outcomes of radiation therapy (RT) for stage IVB uterine cervical cancer (UCC) patients with lung (oligo) metastases due to the lack of recent reports on the subject.
PATIENTS AND METHODS
The cohort for this retrospective study comprised 23 consecutive patients with UCC (squamous cell carcinoma, n=13) and lung metastases who had received pelvic RT. Ten had lung metastases only, including 7 with oligometastases (≤4 lung metastases); the remaining 13 also had other distant metastases.
RESULTS
Nine (39.1%) of the 22 patients (95.7%) completed RT without interruption. The 1-year primary progression-free rate was 95.2%. The 1-year overall survival rate was 47.2 % (estimated median survival: 9 months). Significant prognostic factors for survival included: i) ≤4 lung metastases (p=0.035), ii) unilateral lung metastases (p=0.039), iii) primary tumor diameter <100 mm (p<0.001), and iv) ECOG performance status <1 (p=0.015).
CONCLUSION
RT is safe and effective for stage IVB UCC patients with lung metastases.
背景/目的：由于缺乏关于该主题的近期报道，我们旨在研究放射治疗（RT）在有肺（寡）转移的 IVB 期子宫颈癌（UCC）患者中的作用和结局。
患者和方法
本回顾性研究的队列包括 23 例连续接受盆腔 RT 的 UCC（鳞状细胞癌，n=13）和肺转移患者。其中 10 例仅有肺转移，包括 7 例寡转移（≤4 个肺转移）；其余 13 例还有其他远处转移。
结果
22 例患者中的 9 例（39.1%）无中断地完成了 RT。1 年无进展生存率为 95.2%。1 年总生存率为 47.2%（估计中位生存时间：9 个月）。生存的显著预后因素包括：i）≤4 个肺转移（p=0.035），ii）单侧肺转移（p=0.039），iii）原发肿瘤直径<100mm（p<0.001），和 iv）ECOG 表现状态<1（p=0.015）。
结论
对于有肺转移的 IVB 期 UCC 患者，RT 是安全有效的。
Zotero 插件